EUVIMEDOpdag EUVIMED
Crossref

Dapagliflozin, An SGLT2 Inhibitor, Improves Endothelial Cell Energy Metabolism Through Enhanced Mitochondrial Respiration

Iga Walczak, Alicja Braczko, Aleksandra Paterek, Filip Rolski, Krzysztof Urbanowicz, Maria Tarnawska, Roksana Knapczyk, Aleksandra Parzuchowska, Ryszard T Smoleński, Marcin Hellmann, Michał Mączewski, Barbara Kutryb-Zając

Cellular Physiology and Biochemistry · 2025

DOI: 10.33594/000000772 ↗

At a glance

Journal article in Cellular Physiology and Biochemistry, 2025. Written by Iga Walczak and 11 co-authors. Institution: Department of Biochemistry, Medical University of Gdansk, Gdańsk, Poland. Major MEDLINE topics: Benzhydryl Compounds, Glucosides, Sodium-Glucose Transporter 2 Inhibitors, Energy Metabolism. Cited 8 times so far (Crossref). Funded by: The National Science Centre of Poland (NCN).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND/AIMS: Flozins (sodium-glucose cotransporter 2 inhibitors, SGLT2i) are a new class of antidiabetic drugs that reduce cardiovascular mortality and hospitalization rates in heart failure, regardless of type 2 diabetes status. Besides lowering glycemia by inhibiting renal glucose reabsorption, SGLT2 inhibitors may exert sodium-dependent hemodynamic effects and improve cardiomyocyte energy metabolism, substrate preference, and mitochondrial function. However, their impact on endothelial cells remains largely unknown. This study aimed to analyse the effects and mechanisms of SGLT2i on endothelial cell metabolism and function. METHODS: Mouse cardiac endothelial cells (H5V) were used to test the impact of dapagliflozin on endothelial cell metabolism and function in the presence of hypoxia-mimicking conditions. The concentration of intracellular nucleotides was measured using high-performance liquid chromatography. Mitochondrial and glycolytic activity were assessed using Seahorse XFp, while nitric oxide (NO) production was determined by 4-Amino-5-Methylamino-2',7'-Difluorofluorescein (DAF-FM) fluorescence staining. The effects of dapagliflozin treatment on endothelial NO synthesis were also analysed in patients with chronic heart failure and left ventricular ejection fraction above 40% and C57Bl/6J mice. RESULTS: Dapagliflozin augmented adenosine triphosphate (ATP) levels and the ATP/ADP (adenosine diphosphate) ratio in cultured endothelial cells correlated to increased NO production. Dapagliflozin-treated endothelial cells produced ATP through both mitochondrial respiration and glycolysis. Interestingly, mitochondrial respiration was enhanced, while glycolysis was unaffected in endothelial cells after in vitro dapagliflozin treatment. In a murine model, dapagliflozin doubled the rate of coronary NO synthesis and tended to improve coronary capillary density. In humans with chronic heart failure, 3-month treatment with dapagliflozin revealed many metabolic effects, suggesting potential mechanisms related to nitric oxide homeostasis, mitochondrial function, and L-arginine metabolism. CONCLUSION: This study demonstrated the beneficial effect of dapagliflozin on endothelial cell metabolism and function. Regulation of endothelial cell bioenergetics may be an undervalued mechanism of SGLT2i to delay heart failure progression and support cardiac regeneration. These may accelerate endothelial-targeted strategies to support heart failure treatment.

Subjects

MeSH terms (MEDLINE)

Benzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 InhibitorsEnergy MetabolismEndothelial CellsMitochondriaAnimalsMiceMice, Inbred C57BLNitric OxideHumansMaleHeart FailureSodium-Glucose Transporter 2Cell LineCell Respiration

Author keywords

Dapagliflozin; Cardiac endothelial cells; Nitric oxide; Energy metabolism

Substances

Benzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsNitric OxideSodium-Glucose Transporter 2

Authors and institutions

  • Department of Biochemistry, Medical University of Gdansk, Gdańsk, Poland.
  • Department of Clinical Physiology, The Centre of Postgraduate Medical Education, Warsaw, Poland.
  • Department of Cardiac Diagnostics, Medical University of Gdansk, Gdańsk, Poland.
  • Department of Biochemistry, Medical University of Gdansk, Gdańsk, Poland, b.kutryb-zajac@gumed.edu.pl.
  • Centre of Experimental Cardiooncology, Medical University of Gdansk, Gdańsk, Poland.

Funding

  • The National Science Centre of Poland (NCN)

Cite

APA

Walczak, I., Braczko, A., Paterek, A., Rolski, F., Urbanowicz, K., Tarnawska, M., Knapczyk, R., Parzuchowska, A., Smoleński, R. T., Hellmann, M., Mączewski, M., & Kutryb-Zając, B. (2025). Dapagliflozin, An SGLT2 Inhibitor, Improves Endothelial Cell Energy Metabolism Through Enhanced Mitochondrial Respiration. Cellular Physiology and Biochemistry. https://doi.org/10.33594/000000772

Vancouver

Walczak I, Braczko A, Paterek A, Rolski F, Urbanowicz K, Tarnawska M, et al. Dapagliflozin, An SGLT2 Inhibitor, Improves Endothelial Cell Energy Metabolism Through Enhanced Mitochondrial Respiration. Cellular Physiology and Biochemistry. 2025. doi:10.33594/000000772

BibTeX
@article{Walczak2025,
  author = {Walczak, Iga and Braczko, Alicja and Paterek, Aleksandra and Rolski, Filip and Urbanowicz, Krzysztof and Tarnawska, Maria and Knapczyk, Roksana and Parzuchowska, Aleksandra and Smoleński, Ryszard T and Hellmann, Marcin and Mączewski, Michał and Kutryb-Zając, Barbara},
  title = {Dapagliflozin, An SGLT2 Inhibitor, Improves Endothelial Cell Energy Metabolism Through Enhanced Mitochondrial Respiration},
  journal = {Cellular Physiology and Biochemistry},
  year = {2025},
  doi = {10.33594/000000772}
}
Start for free →